araag2/HINT huggingface dataset:
Clinical trial NCT00193921 (phase 2, status: completed)
Conditions: non small cell lung carcinoma
ICD codes: D02.20, D02.21, D02.22
Drugs: vinorelbine, gemcitabine, cisplatin
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically proven non-small cell lung cancer.

          -  Planned high dose palliative radiation therapy for locoregional control. Examples
             include patients with:

               1. Stage I - IIIB disease with

                    -  disease technically unsuitable for radical therapy, or · weight loss in
                       excess of 10%, or

                    -  concurrent medical illness

               2. Patients found to have a locally advanced thoracic disease suitable for radical
                  therapy but on work up are found to have a FDG-PET only solitary metastasis.

          -  All potential patients, prior to registration, must be reviewed at a multidisciplinary
             lung oncology meeting attended by medical oncologists, radiation oncologists and
             radiologists.

          -  No prior radiotherapy or chemotherapy for non-small cell lung cancer.

          -  ECOG performance status 0, 1.

          -  Adequate hepatic, bone marrow and renal function.

          -  If patient is female of child bearing potential, she must not be pregnant or
             lactating. Males and females of reproductive potential must practise adequate
             contraception.

          -  Written informed consent.

        Exclusion Criteria:

          -  Patient unable to receive all therapy as an outpatient.

          -  Significant medical conditions which in the opinion of the investigator would
             compromise the planned delivery of the chemotherapy and radiotherapy or which may be
             potentially exacerbated by these modalities.

          -  History of any other cancer (except non-melanoma skin cancer or carcinoma in situ of
             the cervix) unless in complete remission and off all therapy for that cancer for at
             least 5 years.

          -  Receiving treatment with another investigational agent.
Clinical trial NCT00656916 (phase 2, status: terminated)
Conditions: bronchiolitis
ICD codes: J21.9, J84.115, J21.1, J21.0, J21.8
Drugs: fluticasone propionate
SMILES: OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
Reason stopped: 
    terminated due to slow accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patients >/=18 years of age.

          2. Patients must be engrafted and at least 80 days post allogeneic hematopoietic stem
             cell transplantation.

          3. New onset airflow obstruction defined as decline of forced expiratory volume in 1
             second (FEV1) percent predicted >/= 15%.

          4. Total Lung Capacity (TLC) > 85% to rule out restrictive lung disease.

          5. Patient must be willing to comply with all study procedures and capable of signing
             informed consent.

        Exclusion Criteria:

          1. Patients with active pulmonary infection.

          2. Patients with known hypersensitivity to corticosteroids
Clinical trial NCT00003219 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: perillyl alcohol
SMILES: CC1=NC(C)=C(OC[C@]2(C[C@H]2C(=O)NC2=CC=C(F)C=N2)C2=CC=CC(F)=C2)C=N1
Eligibility criteria:

        DISEASE CHARACTERISTICS: Microscopically confirmed metastatic breast cancer Must be
        refractory or have recurred after at least 1 systemic chemotherapy regimen Estrogen
        receptor positive tumors must have failed or recurred after hormonal therapy At least 1
        site of measurable disease required Previously radiated lesions are not considered
        measurable unless there is evidence of disease progression after completion of radiation
        therapy No known brain metastases Hormone receptor status: Unspecified

        PATIENT CHARACTERISTICS: Age: 18 and over Menopausal status: Not specified Performance
        status: Zubrod 0-2 Life expectancy: At least 12 weeks Hematopoietic: WBC at least 4000/mm3
        Platelet count at least 100,000/mm3 Absolute neutrophil count at least 1500/mm3 Hepatic:
        Bilirubin no greater than 1.5 mg/dL SGOT no greater than 2 times normal Renal: Creatinine
        no greater than 1.5 mg/dL BUN no greater than 30 mg/dL Other: Effective birth control must
        be used by fertile patients (barrier method preferred) Not pregnant or nursing

        PRIOR CONCURRENT THERAPY: Recovered from toxic effects of prior treatment Biologic therapy:
        No immunologic therapy within the past 2 weeks Chemotherapy: No chemotherapy within the
        past 4 weeks (6 weeks for mitomycin or nitrosoureas) See Disease Characteristics Endocrine
        therapy: No hormonal therapy within the past 2 weeks See Disease Characteristics
        Radiotherapy: No radiotherapy within the past 4 weeks See Disease Characteristics Surgery:
        Not specified Other: No concurrent cholesterol lowering agents, supplemental vitamins, or
        other antioxidants
Clinical trial NCT00530634 (phase 2, status: terminated)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: cisplatin, gemcitabine hydrochloride
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed single, primary bronchogenic non-small cell
             lung cancer meeting the following subtypes:

               -  Adenocarcinoma (no bronchioalveolar cell histology)

               -  Squamous cell carcinoma

               -  Large cell carcinoma

          -  Meeting the following staging criteria:

               -  Stage IIB (T2, N1, M0, or T3, N0, M0)

               -  Stage IIIA (T1-3, N2, M0 or T3, N1, M0)

               -  Stage IIIB (Any T, N3, M0 or T4, Any N, M0)

          -  No more than 1 parenchymal lesion in the same lung or in both lungs

          -  No tumor involving the superior sulcus (e.g., Pancoast tumor)

          -  Patients must undergo evaluation by the involved thoracic surgeon, medical oncologist,
             and radiation oncologist prior to registration

          -  No evidence of metastatic disease

               -  Biopsy or aspiration cytology required to confirm the benign diagnosis of CT or
                  MRI abnormalities that potentially represent metastatic disease

               -  Biopsy required if all noninvasive tests are indeterminant

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 70-100%

          -  Absolute granulocyte count ≥ 1,500/μL

          -  Platelet count ≥ 100,000/μL

          -  Bilirubin ≤ 3 times upper limit of normal (ULN)

          -  SGOT and SGPT ≤ 3 times ULN

          -  Creatinine clearance > 50 mL/min

          -  No prior malignancy except adequately treated basal cell or squamous cell skin cancer,
             carcinoma in situ of the cervix, ductal or lobular carcinoma in situ of the breast, or
             any other cancer from which the patient has been disease-free for 5 years

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective protection

          -  No significant hearing loss or patient unwilling to accept potential for further
             hearing loss

          -  No uncontrolled medical illness by appropriate medical therapy (e.g., myocardial
             infarction within the past 3 months or liver cirrhosis)

          -  No symptomatic peripheral neuropathy affecting activities of daily living

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy or radiotherapy for lung cancer
Clinical trial NCT00395577 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: vx-702
SMILES: NC(=O)N(C1=CC=C(C(N)=O)C(=N1)C1=CC=C(F)C=C1F)C1=C(F)C=CC=C1F
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients 18 to 75 years of age with active RA

          -  Must have been taking MTX for at least 6 months

          -  No concurrent DMARD treatment (other than a stable dose of MTX)

        Exclusion Criteria:

          -  Planned major surgery (e.g., joint replacement) within the duration of the treatment
             period of the study

          -  Treated with intra-articular injections of corticosteroids within 28 days prior to Day
             1
Clinical trial NCT01535222 (phase 2, status: completed)
Conditions: coronary artery bypass graft, cardiopulmonary bypass
ICD codes: Q93.81, B33.4, A36.81, A50.54, A52.00, A52.09, B33.24
Drugs: mdco-2010, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria

          -  Men, aged 18 to 80 years or

          -  Post-menopausal women, aged up to 80 years. Postmenopausal status defined as ≥ 1 year
             since last menstruation in women with no medical history of hysterectomy or women with
             a medical history of bilateral oophorectomy

          -  Planned elective, isolated primary CABG surgery with more than 1 graft, including the
             use of cardiopulmonary bypass

          -  Written informed consent prior to any study-related procedure not part of normal
             medical care

        Exclusion Criteria

        Patients may not meet any of the following exclusion criteria:

          -  Planned concomitant surgery including atrial septal defect (ASD) repair, valve
             replacement, carotid endarterectomy, aortic surgery, any combined procedure or any
             repeat sternotomy

          -  Planned Off-pump CABG

          -  Body weight < 55 kg or > 110 kg

          -  Planned hypothermia < 28°C

          -  Major surgical procedures within 30 days of entry

          -  Placement of drug-eluting stent (DES) within 12 months or of bare-metal stent (BMS)
             within 6 weeks of entry in a vessel which is not intended to be grafted

          -  Ejection fraction < 35%

          -  Preoperative coagulation abnormalities

               -  Platelet count < 100,000/cubic mm, or

               -  INR > 1.5 or Quick < 40%, or

               -  activated partial thromboplastin time (aPTT) > 1.5 x upper limit of normal (ULN)

          -  Preoperative Hb < 11 g/dL for male patients or < 10 g/dL for female patients

          -  Patient refusal to receive donor blood products if necessary

          -  Administration of thienopyridines within 5 days prior to surgery Administration of
             warfarin within 5 days prior to surgery

          -  Administration of tirofiban or eptifibatide within 24 hours or administration of
             abciximab within 5 days prior to surgery

          -  Administration of fondaparinux within 24 hours prior to surgery

          -  Creatinine clearance (calculated using Cockroft-Gault equation) < 60 mL/min

          -  Planned intraoperative use of tranexamic acid or of ε-aminocaproic acid

          -  History of stroke or transient ischemic attack within 3 months prior to entry

          -  Known heparin-induced thrombocytopenia

          -  Known history of thrombophilia, eg, deep vein thrombosis (DVT) with pulmonary embolism

          -  Active liver disease

          -  Any condition requiring chronic immunosuppressive medication

          -  Receipt of an investigational drug or device 30 days prior to entry

          -  Any other condition which, in the opinion of the investigator, would prevent a
             patient's participation in the study
Clinical trial NCT00734149 (phase 2, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: bortezomib, melphalan, prednisone
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have histologically confirmed multiple myeloma, defined as at least one
             of the following major criteria and one minor criterion or at least three minor
             criteria:

        Major Criteria Minor Criteria Plasmacytoma on tissue biopsy Marrow plasmacytosis 10-29%
        Marrow plasmacytosis ≥ 30% Monoclonal protein present, less than major criteria Monoclonal
        protein: Lytic bone lesions

        Immunoglobulin G (IgG) > 3.5 g/dl Decrease in uninvolved immunoglobulins:

        Immunoglobulin A (IgA) > 2 g/dl Immunoglobulin M (IgM) < 50 mg/dl Bence Jones ≥ 1 g/24 hr
        IgA < 100 mg/dl IgG < 600 mg/dl

          -  No prior therapy

          -  Life expectancy greater than 3 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status <3 (Karnofsky >40%

          -  Patients must have normal organ and marrow function. Patients with severe pancytopenia
             due to myeloma involvement of the bone marrow and patients with renal insufficiency
             (creatinine > 2 mg/dl) due to myeloma will also be included.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Pregnant women

          -  Patients may not be receiving any other investigational agents.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to bortezomib, melphalan, or other agents used in the study.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Patients with immune deficiency are at increased risk of lethal infections when
             treated with marrow-suppressive therapy. Therefore, HIV-positive patients receiving
             combination anti-retroviral therapy are excluded from the study because of possible
             pharmacokinetic interactions with bortezomib or other agents administered during the
             study.
Clinical trial NCT00313781 (phase 2, status: completed)
Conditions: prostatic neoplasms
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1
Drugs: cp-751,871, docetaxel, prednisone, docetaxel, prednisone
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of metastatic, progressive hormone refractory prostate cancer

          -  Adequate bone marrow, liver and kidney function

        Exclusion Criteria:

          -  Previous treatment with chemotherapy
Clinical trial NCT01726517 (phase 2, status: completed)
Conditions: chronic hepatitis c virus
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: ldv/sof, rbv
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 18 years, with chronic genotype 1 HCV infection

          -  HCV RNA equal to or greater than 10,000 IU/mL at screening

          -  Cirrhosis determination; a liver biopsy may be required

          -  Screening laboratory values within defined thresholds

          -  Use of two effective contraception methods if female of childbearing potential or
             sexually active male

        Exclusion Criteria:

          -  Pregnant or nursing female or male with pregnant female partner

          -  Current or prior history of clinical hepatic decompensation

          -  Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain resolved
             skin cancers)

          -  Chronic use of systemic immunosuppressive agents

          -  History of clinically significant illness or any other medical disorder that may
             interfere with subject treatment, assessment or compliance with the protocol
Clinical trial NCT01067859 (phase 2, status: terminated)
Conditions: acute heart failure
ICD codes: I50.811, I50.21, I50.31, I50.813, I50.23, I50.33, I50.41
Drugs: cinaciguat (bay58-2667), cinaciguat (bay58-2667), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and non-pregnant, non-lactating female subjects, age >/= 18 years of age; or
             women without childbearing potential defined as postmenopausal women aged 55 years or
             older, women with bilateral tubal ligation, women with bilateral ovariectomy, and
             women with a hysterectomy

          -  Subjects must have the clinical diagnosis of Congestive Heart Failure (CHF) made at
             least three months prior to enrollment

          -  Subjects must experience worsening of both of the symptoms below leading to
             hospitalization at the time of entry into the study:

               -  dyspnea and

               -  clinical evidence of volume overload

        Exclusion Criteria:

          -  Acute de-novo heart failure

          -  Acute myocardial infarction and/or myocardial infarction within 30 days

          -  Valvular heart disease requiring surgical intervention during the course of the study

          -  Heart failure due to or associated with uncorrected primary valvular disease,
             malfunctioning artificial heart valve, or uncorrected congenital heart disease

          -  Primary hypertrophic cardiomyopathy

          -  Acute inflammatory heart disease, eg, acute myocarditis

          -  Unstable angina requiring angiography
Clinical trial NCT01543854 (phase 2, status: completed)
Conditions: acute heart failure
ICD codes: I50.811, I50.21, I50.31, I50.813, I50.23, I50.33, I50.41
Drugs: rlx030, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients hospitalized or requiring admission to hospital for management of acute heart
             failure within the previous 48 hours.

          -  Pulmonary wedge pressure above or equal to18 mmHg determined by right heart
             catheterization

        Exclusion Criteria:

          -  Systolic blood pressure below 115 mmHg

          -  Significant valvular diseases or arrythmias

          -  Acute coronary syndrome in previous 45 days

          -  Treatment with mechanical support (intra-aortic balloon pump, endotracheal intubation,
             mechanical ventilation, or any ventricular assist device)

          -  Impaired renal or hepatic function

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01494233 (phase 2, status: completed)
Conditions: irritable bowel syndrome
ICD codes: K58.2, K58.8, K58.0, K58.1, K58.9
Drugs: 250 mg lx1033 tablets, placebo tablet
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female subjects, aged 18 to 70 years, with diarrhea-predominant IBS (IBS-D)
             with symptom onset at least 6 months prior to diagnosis

          -  Two or more days per week with at least one stool with a consistency of Type 6 or 7
             (Bristol Stool Form Scale)

          -  Weekly average of worst abdominal pain in past 24 hours score of greater than or equal
             to 3.0 using a 0-10 point scale

          -  Ability to provide written, informed consent

        Exclusion Criteria:

          -  Inability to discontinue any current drug therapy for IBS, with the exception of
             bulking agents. Subjects will be allowed up to 2 doses of loperamide per week as
             rescue medication.

          -  Subjects who score severe abdominal pain (rated 7 or higher) 5 or more days per week

          -  Concomitant use of opioid analgesic drugs or drugs that affect bowel motility

          -  Any abnormalities or conditions deemed by the investigator as clinically significant
Clinical trial NCT00142038 (phase 2, status: completed)
Conditions: stomach neoplasm, neoplasm metastasis
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: docetaxel, capecitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with histologically proven adenocarcinoma of the stomach or the GE-junction.

          -  Patients with distant metastases or patients with locally advanced disease who are not
             curatively operable proven by laparoscopy or patients with a recurrence after
             gastrectomy.

          -  Patients who did not receive any prior palliative chemotherapy. An adjuvant
             chemotherapy is allowed.

          -  Age between 18 and 75 years.

          -  Sufficient bone marrow function defined as leucocytes > 3.0 Gpt/l, thrombocytes > 100
             Gpt/l

          -  Sufficient liver function defined as bilirubin < 1.5 mg/dl (1.5 x ULN), ALT and AST <
             3 x ULN.

          -  Sufficient renal function defined as serum creatinine < 1.25 x ULN, or creatinine
             clearance > 60 ml/min calculated according to Cockroft-Gault

          -  Contraception in patients with reproductive potential.

          -  Karnofsky-performance-index at least 60%

          -  Measurable tumor lesions.

          -  Written informed consent of the patient.

        Exclusion Criteria:

          -  Karnofsky-performance-index less or equal 50%.

          -  Patients who already received a palliative first-line chemotherapy.

          -  Prior second malignancy, except basal cell carcinoma of the skin or curatively treated
             carcinoma in situ of the cervix.

          -  Parallel radiation therapy

          -  Uncontrolled infection.

          -  CNS-metastasis

          -  Other severe medical disease

          -  Prior major surgery for less than 2 weeks

          -  Parallel treatment with other experimental therapies.

          -  Parallel treatment with any other therapy aiming against the tumor.

          -  Chronic diarrhea, subileus.

          -  Chronic inflammatory bowel disease or intestinal obstruction.

          -  Unable to take oral medication.

          -  Pregnancy or breast feeding.